I

Immutep Limited
D

IMMP

1.72000
USD
0.03
(1.78%)
مغلق
حجم التداول
209
الربح لكل سهم
-20
العائد الربحي
-
P/E
-8
حجم السوق
250,361,408
أصول ذات صلة
A
ADPT
0.100
(0.94%)
10.760 USD
A
ATNM
-0.05500
(-3.01%)
1.77500 USD
B
BCRX
0.00000
(0.00%)
8.55500 USD
M
MRKR
0.05000
(3.31%)
1.56000 USD
R
RCKT
-0.07500
(-2.33%)
3.14000 USD
T
TTNP
-0.81000
(-15.52%)
4.41000 USD
المزيد
الأخبار المقالات

العنوان: Immutep Limited

القطاع: Healthcare
الصناعة: Biotechnology
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.